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Updated Meta-Analysis of Septal Alcohol Ablation
Versus Myectomy for Hypertrophic Cardiomyopathy
Shikhar Agarwal, MD, MPH,* E. Murat Tuzcu, MD,† Milind Y. Desai, MD,†
Nicholas Smedira, MD,‡ Harry M. Lever, MD,† Bruce W. Lytle, MD,‡ Samir R. Kapadia, MD,†
Cleveland, Ohio
Objectives The purpose of this study was to perform a systematic review and meta-analysis of comparative studies to com-
pare outcomes of septal ablation (SA) with septal myectomy (SM) for treatment of hypertrophic obstructive car-
diomyopathy (HOCM).
Background SM is considered the gold standard for treatment of HOCM. However, SA has emerged as an attractive therapeu-
tic alternative.
Methods A Medline search using standard terms was conducted to determine eligible studies. Due to a lack of random-
ized control trials, we included observational studies for review.
Results Twelve studies were found eligible for review. No significant differences between short-term (risk difference [RD]:
0.01; 95% confidence interval [CI]: 0.01 to 0.03) and long-term mortality (RD: 0.02; 95% CI: 0.05 to 0.09)
were found between the SA and SM groups. In addition, no significant differences could be found in terms of
post-intervention functional status as well as improvement in New York Heart Association functional class, ven-
tricular arrhythmia occurrence, re-interventions performed, and post-procedure mitral regurgitation. However, SA
was found to increase the risk of right bundle branch block (RBBB) (pooled odds ratio [OR]: 56.3; 95% CI: 11.6
to 273.9) along with need for permanent pacemaker implantation post-procedure (pooled OR: 2.6; 95% CI: 1.7
to 3.9). Although the efficacy of both SA and SM in left ventricular outflow tract gradient (LVOTG) reduction
seems comparable, there is a small yet significantly higher residual LVOTG amongst the SA group patients as
compared with the SM group patients.
Conclusion SA does seem to show promise in treatment of HOCM owing to similar mortality rates as well as functional sta-
tus compared with SM; however, the caveat is increased conduction abnormalities and a higher post-intervention
LVOTG. The choice of treatment strategy should be made after a thorough discussion of the procedures with the
individual patient. (J Am Coll Cardiol 2010;55:823–34) © 2010 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.09.047t
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“eptal myectomy (SM) has been regarded as the gold
tandard for treatment of hypertrophic obstructive cardio-
yopathy (HOCM). The less-invasive septal ablation (SA)
s rapidly emerging as an attractive alternative for treatment
f HOCM. The number of SAs performed worldwide since
ts introduction in 1995 has now reached over 5,000 (1,2),
urpassing the number of SM performed over the last 45
ears. It is estimated that SA procedures are 15 to 20 times
ore common than SM for HOCM (2). At some centers,
he frequency of SM has been reduced by over 90% in favor
f performing SA as definitive treatment strategy (1).
Septal myectomy has been shown to be effective in
liminating left ventricular outflow tract (LVOT) obstruc-
rom *Internal Medicine, †Cardiovascular Medicine, and ‡Cardiovascular Surgery,
leveland Clinic, Cleveland, Ohio.o
Manuscript received June 10, 2009; revised manuscript received August 31, 2009,
ccepted September 7, 2009.ion, resulting in reduction in sudden death and improve-
ent in functional status (3). The technique has low
ost-operative morbidity and mortality (3). The short-term
nd medium-term data for SA have been encouraging as
ell. However, long-term data are scarce and are the subject
f further research.
We aimed to carry out a systematic review and meta-
nalysis of the available evidence to compare the outcomes
fter SA and SM. Due to the conspicuous absence of
andomized trials, observational studies have been used to
ynthesize evidence.
ethods
earch strategy. Medline search was conducted with
erms like “septal ablation,” “septal myocardial ablation,”
non surgical septal reduction,” “transcoronary ablation
f septal hypertrophy,” “percutaneous transluminal septal
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ablation” in association with “car-
diomyopathy, obstructive,” “car-
diomyopathy, familial,” or “cardio-
myopathy, hypertrophic.”
Study characteristics. We in-
cluded all observational studies
(prospective/retrospective cohort
and case control studies) com-
paring the outcome of SA with
SM in adult patients with refrac-
tory HOCM. Case series and
case reports were excluded from
the review.
Outcome measures. Primary out-
come was defined as 30-day all-
cause mortality. Secondary out-
comes included functional status,
reinterventions, pacemaker inser-
tions, ventricular arrhythmias, car-
diac dimensions, mitral regurgita-
tion (MR), systolic anterior motion
(SAM) of mitral valve (MV),
length of hospital stay, and exer-
cise tolerance.
Meta-analysis. Meta-analysis
was conducted with “metan” func-
tion in Stata version 10.0 (Stata-
Corp, College Station, Texas). Un-
less significant heterogeneity was
encountered, fixed-effects model-
ing was used. Odds ratios (ORs),
risk differences (RDs), and stan-
ardized mean differences (SMDs) were used to report pooled
stimates. Assessment of heterogeneity (I250%; p 0.05)
as achieved by comparing baseline characteristics and
ethodology differences across studies. In cases of signifi-
ant heterogeneity, random effects meta-analysis was con-
ucted. The random effects model was explored with
eta-regression techniques incorporating covariates,
amely country of study and follow-up duration, to evaluate
he reasons for heterogeneity.
Two strategies were adopted for analysis of left ven-
ricular outflow tract gradient (LVOTG) and New York
eart Association (NYHA) functional class. We first
ompared the post-procedure measurement between the
groups to assess the equivalence of the end point. The
econd strategy involved determination of the change
ccurring after procedure compared with pre-intervention
ime for both the groups. This change was subsequently
ompared between the 2 groups. To obtain mean change
nd SD of the difference, variances were imputed with
he p values mentioned. In circumstances where the
ifference was reported as p  0.05, p  0.001, and so
Abbreviations
and Acronyms
CHB  complete heart
block
CI  confidence interval
HOCM  hypertrophic
obstructive cardiomyopathy
ICD  implantable
cardioverter-defibrillator
IVS  interventricular
septum
LBBB  left bundle
branch block
LVOT  left ventricular
outflow tract
LVOTG  left ventricular
outflow tract gradient
MR  mitral regurgitation
MV  mitral valve
NYHA  New York Heart
Association
OR  odds ratio
RBBB  right bundle
branch block
RD  risk difference
SA  septal ablation
SAM  systolic anterior
motion (of mitral valve)
SM  septal myectomy
SMD  standardized mean
differenceorth, the upper level of the p value was considered, eecause this resulted in a conservative estimate and
own-weighting of the studies in the meta-analysis,
hich failed to provide accurate p values. In case of
bsence of meaningful p values, the variance was imputed
ith calculated correlation coefficients per strategies well-
escribed elsewhere (4,5).
esults
he search strategy retrieved 288 title-abstracts for review.
f these, 177 lacked a control/comparison group; 39 were
ase reports or case series; and 60 were reviews, consensus
rticles, or expert opinion on the subject. Twelve retrospec-
ive cohort studies (6–17) were included for data extraction
nd analysis. Studies from the Mayo clinic (6,7,12) were
erived from the same database. Hence, the study encom-
assing the larger time frame (1998 to 2006) was included
7). In the Cleveland Clinic experience, conduction abnormal-
ties and mortality outcomes were derived from follow-up
tudies (15,16). Other clinical and echocardiographic end
oints were derived from the original study (14).
Table 1 depicts the baseline characteristics of included
tudies. It also provides an insight into potential biases in
ach study impacting our inferences. Tables 2 and 3
emonstrate the estimated effect sizes for comparisons
etween SA and SM groups in terms of clinical and
chocardiographic parameters, respectively. None of the
tudies reported differences in short-term mortality, ar-
hythmias, and re-interventions. Jiang et al. (13) reported a
ignificantly higher long-term mortality in the SM group
han the SA group. On the contrary, Ralph-Edwards et al.
9) reported higher long-term mortality in the SA group.
o significant difference in adjusted 4-year survival rates was
bserved in the Mayo clinic experience (7). However, survival
ree of death and severe symptoms was lower among patients
ge 65 years undergoing SA than those undergoing SM.
Two studies (9,14) reported higher mean NYHA func-
ional class after SA than after SM. These studies also
eported higher LVOTG after ablation than after myec-
omy. However, no significant differences were discernible
n NYHA functional class reduction or LVOTG reduction
fter the procedure in any study. Table 4 presents pooled
stimates for all outcomes. No significant short-term or
ong-term mortality benefit was apparent, yet a significantly
igher rate of pacemaker implantation and a higher
VOTG were observed after ablation than after myectomy.
ortality. No study reported a significant difference in
hort-term mortality between the 2 groups (Fig. 1). On
ooled analysis, the RD for short-term mortality between
A and SM groups was insignificant (RD: 0.01; 95%
onfidence interval [CI]: 0.01 to 0.03, p  0.35).
A random effects meta-analysis was performed to com-
are long-term mortality, due to significant heterogeneity.
o statistical difference was observed (RD: 0.02; 95% CI:
0.05 to 0.09). Baseline demographic and clinical differ-nces (Table 1) between the 2 groups likely accounted for
Baseline CharacteristicsTable 1 Baseline Characteristics
First Author/
Year (Ref. #)
Center/Country
Study Period Inclusion Criteria SA/SM,n
Characteristic Differences
Between Study Groups Matching
SA/SM
Outcomes Reported
Age, yrs
Mean (SD) % Men Follow-Up
Sorajja 2008 (7) Mayo Clinic, U.S.
1998–2006
NYHA III–IV or CCS III–IV
refractory to medical
treatment; resting gradient
30 mm or 50 mm with
provocation; IVS 15 mm,
no MV disease
138/123 More hypertension and
CAD in SA; higher
LVOTG among SA group
Age and sex 61 (19)/
60 (19)
39/39 4 yrs/4 yrs Mortality, pacemaker insertions,
heart blocks, ventricular
arrhythmias, tamponade,
functional status,
reinterventions, cardiac
dimensions
Nagueh 2001 (8) Baylor and Mayo,
U.S.,
NR
Resting LVOTG 40 mm,
IVS of at least 15 mm
41/41 None that were measured Age LVOTG 49 (17)/
49 (16)
NR 1 yr/1 yr Mortality, pacemakers, heart
blocks, ICD insertions,
functional class, ventricular
arrhythmias, reinterventions,
MR, AR, exercise tolerance,
cardiac dimensions
Vural 2007 (11) Turkey
2002–2006
LVOTG 50 mm, IVS of at
least 17 mm
16/24 Higher clinical symptoms,
lower LVOT, lower MR,
lower SAM in SA
NR 25 (7.3)/
24 (6.6)
88/83 1 yr/1 yr Mortality, pacemaker, heart
blocks, functional status,
reinterventions, cardiac
dimensions, hospital stay
duration, MR, SAM
Ralph-Edwards
2005 (9)
Canada
1998–2003
Symptomatic adults with HOCM 54/48 Higher age, higher SBP,
higher CAD, better NYHA
class, decreased
posterior wall thickness
and IVS in SA group
NR 59 (15)/
46 (17)
48/63 5 yrs/5 yrs Mortality, pacemaker, functional
status, cardiac dimensions,
composite outcomes,
hospital stay duration, MR,
SAM
Firoozi 2002 (17) United Kingdom
1990–2000
Resting LVOTG 50 mm,
NYHA of at least II
20/24 Higher age in SA group Clinical features, cardiac
dimensions, LVOTG,
exercise parameters
49 (13)/
38 (16)
60/54 1 yr/1 yr Mortality, pacemakers,
functional status, cardiac
dimensions, exercise
tolerance
Jiang 2004 (13) China
1994–2002
Resting LVOTG 30 mm,
provocable LVOTG 50 mm,
IVS 15 mm, NYHA III or
CCS III or syncope 2/m
43/11 NR NR 45 (13–74)/
36 (11–69)*
NR 2 yrs/2 yrs Mortality, pacemakers, heart
blocks, ventricular
arrhythmias, reinterventions,
cardiac dimensions,
van der lee
2005 (10)
the Netherlands
1986–1999 SM
1999–2005 SA
Resting/provocable LVOTG
50 mm, mitral leaflet
area 12 cm2
43/29 Higher age, lower MR
grade in SA
NR 52 (17)/
44 (12)
NR 1 yr/1 yr Mortality, pacemakers, ICD
insertions, functional status,
ventricular arrhythmias,
reinterventions, cardiac
dimensions, MR, SAM, mitral
leaflet area
Qin 2001 (14) Cleveland Clinic, U.S.
1997–1999*
Severe symptoms refractory to
medical treatment with
resting or provocable
LVOTG 50 mm
25/26† Higher SBP, comorbidities,
more women, higher
age in SA group
NR 63 (14)/
48 (13)
28/62 3 months/
3 months*
Mortality, pacemakers, heart
blocks, functional status,
reinterventions, cardiac
dimensions, MR, SAM,
hospital stay duration
*Mean (range). †Follow-up studies: Kwon et al. (16) reporting outcomes on mortality up to 2000; n 55 (SA)/98 (SM). Mean follow up period in both groups was 8 years. Qin et al. (15) reporting outcomes on heart block and pacemakers up to 2004; n 70 (SA)/134 (SM).
AR aortic regurgitation; CCS Canadian Cardiovascular Society; ICD implantable cardioverter defibrillator; IVS interventricular septum; LA left atrium; LBBB left bundle branch block; LVEDD left ventricular end diastolic diameter; LVEF left ventricular ejection
fraction; LVESD left ventricular end systolic diameter; LVOTG left ventricular outflow tract gradient; MRmitral regurgitation; MVmitral valve; NR not reported; NYHA New York Heart Association functional class (range: I to IV); RBBB right bundle branch block;
SA  septal ablation; SAM  systolic anterior motion; SBP  systolic blood pressure; SM  septal myectomy.
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Septal Alcohol Ablation Versus Septal Myectomy February 23, 2010:823–34he heterogeneity. Older age and more comorbidities were
ncountered in the SA group than the SM group in several
tudies (9,14), which might account for poorer outcomes in
he former group. On meta-regression analysis, no signifi-
ant difference was observed on the basis of the country of
he study (meta-regression coefficient: 0.013, p  0.67).
owever, a significant influence of follow-up duration was
emonstrated (meta-regression coefficient: 0.002; p 
.006), implying that RD for long-term mortality between
A and SM groups increased with corresponding increase in
ollow-up duration, partially explaining the observed
eterogeneity.
acemaker implantation. Figure 2 demonstrates that the
ermanent pacemaker implantation rate was considerably
igher in the SA group, compared with the SM group
pooled OR: 2.6, 95% CI: 1.7 to 3.9). Right bundle branch
lock (RBBB) were more commonly encountered after
blation than after myectomy (pooled OR: 56.3; 95% CI:
1.6 to 273.9). Meta-analysis of post-procedure left bundle
ranch block (LBBB) was limited, due to significant heter-
geneity (I2: 93.7%, p  0.001). Two studies (13,15)
eported a significantly higher LBBB after myectomy,
ompared with after ablation. On the contrary, Vural et al.
11) reported higher LBBB in the SA group. A pooled
stimate/meta-analysis was deemed fallacious in this case.
unctional status. Meta-analysis with random effects
odeling revealed no significant difference in the post-
rocedure NYHA functional class between the 2 study
roups (SMD: 0.30; 95% CI: 0.03 to 0.63) (Fig. 3).
Figure 4 demonstrates the comparison of NYHA func-
ional class reduction after procedure between the SA and
M groups. None of the studies showed significant differ-
nces in NYHA functional class reduction between the 2
trategies. The pooled estimate was statistically insignificant
SMD: 0.27; 95% CI: 0.54 to 0.01).
Cardiopulmonary performance status, with oxygen con-
umption during graded exercise protocols, was reported in
ew studies (8,17). Nagueh et al. (8) reported a highly
ignificant improvement in exercise duration, peak oxygen
onsumption, and METS in both the SA and SM group of
atients. The magnitude of improvement was similar in
oth groups at 1-year follow-up. However, Firoozi et al.
17) reported a superior benefit in performance status with
M during immediate post-procedure and 1-year follow-up
eriods.
V abnormalities. The MR and SAM have been quan-
ified differently across studies. No study (8,9,11) reported a
ignificant difference in the occurrence of post-procedure
oderate-severe MR between the 2 groups. The pooled
R was statistically insignificant (1.44, 95% CI: 0.6 to
.5). van der lee et al. (10) included subjects with an
ncreased mitral leaflet area 12 cm2. Mean pre-
rocedure MR grade was significantly higher in the SM
roup. All SM group patients underwent a concomitant
itral leaflet extension surgery, whereas no MV correc-tion procedure was done in the SA group patients.Co T
S N V R F Ji va Q
A
ll
e
re
po H
Comparison Estimates of Echocardiographic Characteristics Determined After Intervention Between SA and SM GroupsTable 3 Comparison Estimates of Echocardiographic Characteristics Determined After Intervention Between SA and SM Groups
First Author/
Year (Ref. #) MR* SAM* LVOTG†
LVOTG
Reduction† IVS†
IVS
Reduction† LVEDD† LVESD† LVEF† LA Size†
Sorajja 2008 (7) — — 10 19 mm in
SA group
84 60 mm pre-SA
to 10 19 mm
post-SA
— 16 7 g in SA;
6 4 g in SM‡
— — — —
Nagueh 2001 (8) 0.3 (0.01 to 8.2) — 0.3 (0.09 to 0.8) 0.04 (0.5 to 0.4) 0.1 (0.5 to 0.3) 0.1 (0.4 to 0.5) 0.3 (0.1 to 0.7) 0.6 (1.0 to0.1)§ 0.2 (0.2 to 0.6) —
Vural 2007 (11) 3.7 (0.6 to 23) 1.4 (0.3 to 5.6) 0.5 (1.1 to 0.2) 0.12 (0.8 to 0.5) — — 0.1 (0.5 to 0.7) 1.2 (1.9 to0.5)§ — —
Ralph-Edwards
2005 (9)
1.2 (0.4 to 3.9) 4.8 (2.0 to 11.9)§ 0.7 (0.3 to 1.1)§ 0 (0.4 to 0.4) — — — — — —
Firoozi 2002 (17) — — 0.6 (0.06 to 1.2) 0.05 (0.5 to 0.7) 0.2 (0.8 to 0.4) — 0.5 (0.1 to 1.1) 3.2 (2.3 to 4.1)§ 40 7% in SA group
44 9% in SM group
0.1 (0.7 to 0.5)
Jiang 2004 (13) — — 0.4 (0.2 to 1.1) 0.4 (1.1 to 0.3) 14 3 mm in
SA group
24 2 mm pre to
14 3 mm
post in SA group
— — — 38 2 mm in
SA group
van der lee
2005 (10)
0.8 0.8 in
SA group
0.6 0.6 in
SM group¶
1.3 0.9 in
SA group
0.5 0.7 in
SM group#
0.4 (0.1 to 0.8) 0.03 (0.5 to 0.4) 0.3 (0.8 to 0.2) 0.1 (0.6 to 0.4) 0 (0.5 to 0.5) 0.3 (0.2 to 0.7) 0.1 (0.6 to 0.3) 0.1 (0.6 to 0.4)
Qin 2001, 2004
(14,15)
9 3 ml in
SA group
8 5 ml in
SM group**
0.6 0.8 in
SA group
0.6 0.5 in
SM group#
1.2 (0.6 to 1.8)§ 0.1 (0.3 to 0.1) 0.6 (0.1 to 1.2)§ 0.5 (1.1 to 0.02) 0.1 (0.7 to 0.4) — 0.4 (0.2 to 0.9) 0.1 (0.7 to 0.4)
All estimates mentioned as effect size (95% confidence interval). *Odds ratio estimates. †Standardized mean difference estimate. ‡Estimate of weight of myocardial ablation from Sorajja et al. (7) on a smaller subset of patients. §Significant effect estimates; p  0.05
is considered significant. Fractional shortening %. ¶Mean MR grade. #Mean SAM grade. **Mean MR volume.
Abbreviations as in Table 1.
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Pooled Effect Estimates for Outcomes Comparing SA With SMTable 4 Pooled Effect Estimates for Outcomes Comparing SA With SM
Characteristic Pooled Studies (Ref. #s) Estimate Used Fixed/Random Effects
Heterogeneity
Estimate
Pooled Estimate 95% Confidence Interval p ValueI2 (%) p Value
Short-term mortality (7–13,16,17) RD Fixed 0 0.95 0.01 0.01 to 0.03 0.35
Long-term mortality (8–13,16) RD Random 75 0.01 0.02 0.05 to 0.09 0.55*
LBBB (11,13,15) OR Random 94 0.01 0.22 0.002 to 13.28 0.48*
RBBB (8,10,16) OR Fixed 26 0.26 56.33 11.59 to 273.88 0.001
Pacemaker implantation (7,8,10,11,13,15,17) OR Fixed 41 0.12 2.57 1.68 to 3.93 0.001
Ventricular arrhythmias (7,8,10,13) OR Fixed 52 0.10 1.34 0.54 to 3.32 0.52
Re-interventions (8,9,11) OR Fixed 0 0.78 2.37 0.54 to 10.51 0.26
MR (8,9,11) OR Fixed 0 0.39 1.44 0.59 to 3.52 0.49
Post-intervention NYHA class (8–11,14,17) SMD Random 62 0.02 0.30 0.03 to 0.63 0.08
Post-intervention change in NYHA class (10,11,14,17) SMD Fixed 0 0.67 0.27 0.54 to 0.01 0.06
Post-intervention LVOTG (8–11,13,14,17) SMD Random 61 0.02 0.45 0.13 to 0.77 0.01*
Post-intervention change in LVOTG (8–11,13,14,17) SMD Fixed 0 0.91 0.09 0.28 to 0.10 0.35
Post-intervention IVS (8,10,14,17) SMD Random 58 0.07 0.01 0.41 to 0.38 0.95
Post-intervention IVS reduction (8,10,14) SMD Fixed 30 0.23 0.07 0.32 to 0.18 0.59
LVEDD (8,10,11,14,17) SMD Fixed 0 0.52 0.15 0.09 to 0.38 0.22
LVESD (8,10,11,17) SMD Random 96 0.001 0.39 0.99 to 1.76 0.58*
LVEF (8,10,14) SMD Fixed 0.1 0.37 0.13 0.15 to 0.40 0.37
LA size (10,14,17) SMD Fixed 0 1.0 0.12 0.43 to 0.18 0.43
p  0.05 is considered significant. *Questionable validity of interpretation due to high heterogeneity.
OR  odds ratio; RD  risk difference; SMD  standardized mean difference; other abbreviations as in Table 1.
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February 23, 2010:823–34 Septal Alcohol Ablation Versus Septal Myectomyevertheless, the post-procedure MR grade was similar
n the 2 groups.
Ralph-Edwards et al. (9) reported a significantly higher
ost-procedure SAM in patients undergoing SA than those
ndergoing SM (OR: 4.8; 95% CI: 2.0 to 11.9). No
ignificant differences in SAM occurrence were encountered
n other studies (10,11,14).
Figure 1 Short-Term Mortality
Risk difference (RD) estimates between the septal ablation (SA) and septal myect
Figure 2 Post-Intervention Pacemaker Implantation
Odds ratio (OR) estimates between the SA and SM groups. Abbreviations as in Figentricular arrhythmias. None of the studies (7,8,10,13)
bserved a significant difference in post-procedure ventric-
lar arrhythmia occurrence between the 2 groups. The
ooled OR was also statistically insignificant (pooled OR:
.34; 95% CI: 0.5 to 3.3).
Although the need for implantable cardioverter-defibrillators
ICDs) is usually independent of the choice of therapy, Nagueh et
M) groups. CI  confidence interval.omy (Sure 1.
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Septal Alcohol Ablation Versus Septal Myectomy February 23, 2010:823–34l. (8) reported increased requirement of ICD for ventricular
ysrhythmias in patients undergoing SM (4 in SM; 1 in
A). These were based on risk-factor profiles and not
ecessarily on clinical events. van der lee et al. (10) reported
CD placement in 2 patients in the SA group and none in
he SM group.
VOTG reduction. The comparison of post-procedure
VOTG between the 2 groups was limited by significant
eterogeneity (I2: 60.7%; p  0.02). A random effects
nalysis yielded a significantly higher LVOTG after ablation,
ompared with after myectomy (pooled SMD: 0.45; 95% CI:
.1 to 0.8) (Fig. 5). Comparison of the net LVOTG reduction
rom the pre-procedure value failed to show any significant
Figure 3 Post-Procedure Mean NYHA Functional Class
Standardized mean difference (SMD) estimates between the SA and SM groups. N
Figure 4 Post-Procedure NYHA Functional Class Reduction Com
The SMD estimates between the SA and SM groups. Abbreviations as in Figures 1ifference between the 2 strategies (pooled SMD:0.09; 95%
I: 0.3 to 0.1) (Fig. 6).
ther cardiac dimensions. The post-procedure interven-
ricular septum (IVS) thickness was similar between the 2
roups (pooled SMD: 0.01; 95% CI: 0.41 to 0.38). No
ignificant differences in net reduction in IVS thickness after
rocedure were apparent between the 2 groups (pooled SMD:
0.07; 95% CI: 0.32 to 0.18). Besides this, no significant
ifference was observed between the 2 groups in terms of post
rocedure left ventricular end diastolic diameter, ejection frac-
ion, and left atrial size. Data on left ventricular end systolic
iameter were more heterogeneous (I2: 95.5%; p  0.001),
imiting the validity of meta-analysis.
New York Heart Association; other abbreviations as in Figure 1.
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February 23, 2010:823–34 Septal Alcohol Ablation Versus Septal Myectomyeintervention rate and length of hospital stay. No
ignificant difference was observed in the reintervention rate
etween the 2 strategies (pooled OR: 2.37; 95% CI: 0.54 to
0.5; p 0.3). Pooled estimates were not calculated for length
f hospital stay, due to differences in quantification of length of
ospital stay across studies (9,11,14). Two studies reported
horter hospital stay in the SA group, compared with the SM
roup (11,14). However, Ralph-Edwards et al. (9) reported
hat mean hospital stay was 4.1 days longer among the SA
roup patients, compared with SM group patients. The au-
Figure 5 Post-Procedure Left Ventricular Outflow Tract
The SMD estimates between the SA and SM groups. Abbreviations as in Figures 1
Figure 6 Post-Procedure Reduction in Left Ventricular Outflow
The SMD estimates between the SA and SM groups. Abbreviations as in Figures 1hors attributed this longer post-intervention hospital stay to
caution in undertaking a new procedure” and to confirm the
bsence of post-intervention complications.
iscussion
his detailed review quantifies definitive risks and benefits
f SA versus SM for treatment of refractory HOCM, to
acilitate the choice of treatment strategy in an objective
anner. We observed comparable short-term and long-
.
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Septal Alcohol Ablation Versus Septal Myectomy February 23, 2010:823–34erm outcomes between the SA and SM groups. Although
ong-term mortality estimate was limited by significant
eterogeneity, the post-adjustment estimates also indicate
hat the difference in mortality between SA and SM groups
n long-term follow-up is unlikely.
Our meta-analysis is contemporary to a similar study
ublished recently (18). However, this study fails to include
t least 4 key observational studies (7,11,13,16), indicating
he potential weaknesses of the search strategy. Inclusion of
dditional studies in our meta-analysis resulted in compar-
son of 410 patients undergoing SA and 398 patients
ndergoing SM for short-term mortality versus comparison
f 183 patients undergoing SA and 168 patients undergoing
M for the same outcome in the earlier published review.
he estimates provided in our review for long-term mor-
ality are more robust due to inclusion of follow-up studies
n addition to initial published studies. We have included
ncillary outcomes like MR, reintervention rate, and echo-
ardiographic parameters as a part of our review. To
vercome the baseline differences between the 2 study groups,
e have described a novel method to compare the changes in
YHA functional class and LVOTG after procedure.
No significant difference was observed between the 2
roups in terms of post-procedure functional status as well
s the efficacy of intervention determined by the improve-
ent in the functional class (Figs. 3 and 4). A trend toward
better functional outcome after myectomy compared with
blation is apparent. However, the results were statistically
nsignificant. In addition, the prevalence of MR, ventricular
rrhythmias, reintervention rate, and echocardiographic cardiac
imensions were found to be similar between the 2 groups.
The caveat to the widespread use of SA lies in the
ncreased conduction abnormalities observed after ablation.
ur meta-analysis demonstrated increased risk of complete
eart block (CHB) requiring pacemaker implantation after
blation, compared with after myectomy. In addition, a
ignificantly higher post-procedure LVOTG was seen in
he SA group than the SM group; even though the amount
f reduction of LVOTG from baseline values was observed
o be similar between the 2 groups.
ortality. The direct procedure-related mortality ranges
etween 1% and 4% for SA. A large German HOCM
egistry has reported a procedure-related mortality rate of
.2% (19), which is comparable to mortality after myectomy
t experienced surgical centers (20). However, in this
articular registry, 12% of ablation patients had recurrent
isabling symptoms (NYHA functional class III/IV) (19).
everal unpredictable events like sudden cardiac death (21)
nd coronary artery dissections (22) have been reported after
A. The incidence of coronary artery dissections after
blation has been reported as high as 4.4% (6 of 130) (22).
eptal ablation is reported to have a significant impact on
uality of life parameters (23). Patients undergoing SA
eported a significant reduction in psychological distress and
n improvement in overall well-being. oVOT obstruction. The LVOT obstruction in HOCM is
ynamic obstruction contributed by both disproportionately
hick septum and its inappropriate excursions along with the
AM of MV toward the septum. Abnormal papillary
uscles have also been implicated in LVOT obstruction
24). High LVOTG has been shown to be an independent
redictor of clinical outcomes, including mortality (25).
oth SA and SM are effective in reducing LVOTG,
lthough each works through completely different mecha-
isms. The LVOTG reduction after ablation follows a
riphasic response and might take up to 3 months to
ompletely manifest itself (26). On the contrary, SM entails
emoval of the “culprit” myocardium surgically, leading to
n immediate LVOT widening and an instantaneous reduc-
ion in LVOTG. The differences in temporal progression of
VOTG between the 2 groups require further research.
Our meta-analysis revealed a significantly higher LVOTG
fter ablation in comparison with the SM group. It has been
uggested that the maximal provocable gradient after abla-
ion might be higher than that observed after myectomy
14,21). It was initially proposed that HOCM was predom-
nantly a nonobstructive disease, with the majority of the
atients devoid of a sizable resting LVOTG (20). However,
ecent studies have shown that approximately 37% of the
OCM patients have significant resting LVOTG, and
thers demonstrate sizable provocable gradients during
xercise (27). It remains unknown whether higher resultant
esting and provocable LVOTG amounts to a greater
ong-term risk of morbidity and mortality.
onduction abnormalities and arrhythmias. Conduction
bnormalities have been shown to be significantly higher
fter SA as compared with SM. Septal ablation creates a
ransmural septal infarct between the anterior and inferior
ree walls; this area commonly contains the right bundle
ranch, and hence there is an increased propensity toward
BBB after ablation (6). Septal myectomy entails removal
f subendocardial tissue in the anterior septum containing
he left bundle branch fibers, increasing the risk of LBBB in
omparison with SA. Patients with pre-existing RBBB are
ore likely, given these considerations, to need a permanent
acemaker after SA, whereas those with LBBB are more
ikely to need pacing after SA (6). The frequency of CHB
equiring permanent pacemaker therapy after SA has ranged
etween 10% and 33% across studies (6,28,29). High
olume of ethanol injection, bolus ethanol injections, and
njection of more than 1 artery are recognized determinants
f post-ablation CHB (15); thus, targeted and slow injec-
ion with minimum ethanol quantity might help reduce
HB. Some nonrandomized studies have suggested that
eptal myocardial reduction by coil embolization does not
nduce CHB (30). Pacemaker implantation rate after my-
ctomy was 1% in the absence of pre-existing RBBB in
he hands of experienced surgeons (6). It must be pointed
ut that up to 36% of patients with failed SA undergoing
M have required pacemaker implantation for CHB post-
peratively (7).
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February 23, 2010:823–34 Septal Alcohol Ablation Versus Septal MyectomyOur meta-analysis did not demonstrate any significant
ncrease in the occurrence of ventricular arrhythmias after
blation. It is postulated that SA produces a “permanent
rrhythmogenic substrate” in the form of an intramyocardial
car, which could increase the risk of lethal re-entrant
rrhythmias (1). However, histological analysis has revealed
hat this is a sequestered and stabilized scar, which is very
ifferent from that produced as a result of ischemic necrosis
31). It has been recently reported that sustained ventricular
rrhythmias are relatively uncommon after SA, hence sug-
esting that SA is not pro-arrhythmic (32). The risk of
achyarrhythmia induced by SA still remains speculative.
he nonarrhythmogenicity of the scarred myocardium has
ot been rigorously tested and merits further evaluation.
V abnormalities. Mitral valves are often redundant (33)
nd anteriorly displaced in hearts with HOCM. Mitral
egurgitation might occur because of SAM and increased
VOT flow velocity or due to intrinsic MV disease. It is
mportant to know the etiology of MR before embarking on
he treatment choice. Septal ablation will not address MR if
t is due to intrinsic MV abnormality. These patients are
est-treated by SM in conjunction with MV repair. Combin-
ng SM with mitral leaflet extension achieved better results in
atients with dilated MV annulus (10). The hemodynamic
tatus (reduction in MR grade/SAM) was reportedly better in
he SM group than the SA group. Although statistically
nsignificant, a trend toward higher reinterventions and higher
omplication rate was evident after ablation.
nfluence of age on outcomes. In the Mayo Clinic expe-
ience (7), patients 65 years of age had better symptom
esolution and a higher survival after myectomy than abla-
ion. In Cleveland Clinic experience (16), advanced age at
he time of SA was associated with higher long-term
ortality in comparison with the younger patients under-
oing ablation. Advanced age has been shown to be a
ignificant and independent risk factor for intraprocedural as
ell as late occurrence of CHBs (34). The surgical results
ave to be viewed in light of possible selection bias against
lder individuals with multiple comorbidities and because
he excellent surgical outcomes might be limited to very
xperienced centers. Seggewiss et al. (31) demonstrated that
ounger patients with thicker IVS have unsatisfactory reduc-
ion of LVOTG. Similarly, Faber et al. (19) demonstrated that
uboptimal reduction in LVOTG was associated with younger
ge. These studies indicate that SM might be more beneficial
mong younger individuals due to a better relief of obstruction,
hich might directly translate into improved clinical outcome
nd significant long-term mortality benefit.
The success of SA is largely determined by perforator
natomy, most failures being attributed to unfavorable
oronary anatomy with an absent appropriate septal perfo-
ator artery. (20). It is important to determine the exact
echanism of HOCM before choosing the treatment
odality, because concurrent papillary muscle dysfunction,
bnormal papillary muscle insertion, or MV abnormalities
re unlikely to respond to SA and hence are more amenable oo surgical correction. The learning curve for SA is steep,
specially regarding the selection of patients and, to some
xtent, target perforator arteries.
tudy limitations. Table 1 demonstrates that the patients
ndergoing SA and SM are inherently different. It is
resumable that there are different referral patterns for
atients for the 2 procedures at various centers across the
orld accounting for these differences. There are small
umbers of patients in all the included studies, and the
ollow-up period has been relatively short across the studies.
he direct comparisons as drawn in meta-analysis are
arder to interpret, given these baseline differences between
he 2 groups. No randomized trials exist comparing the 2
trategies. It has been proposed that a randomized con-
rolled trial to compare SA and SM is an “unrealistic
onsideration” due to low rates of end points in both
reatment arms (35). A significant heterogeneity was en-
ountered in several comparisons in our analysis. Careful
nferences with a great deal of caution have to be drawn
nder these circumstances. The meta-regression technique,
sed to explain heterogeneity, might be fraught with biases
ttributable to a small number of studies.
onclusions
urrently, the choice of SA versus SM for treatment of
OCM is guided by several considerations (Table 5). Al-
hough SM continues to be the “gold-standard” treatment for
efractory HOCM, SA has emerged to be an attractive
lternative. Short-term and medium-term results after SA have
een encouraging. Although SA offers comparable results in
erms of mortality benefit and functional improvement, it
learly increases the risk of conduction abnormalities requiring
ermanent pacemaker implantation. Extensive discussions
ust be conducted with patients to explain the risks and
enefits of the 2 procedures. It is advisable that SA be
erformed at tertiary level centers by experienced interventional
ardiologists in conjunction with imaging and clinical cardiol-
onsiderations to Decide Choicef Proc dure for Treatm nt of HOCMTable 5 C nsideratio s t Decide Choiceof Procedure for Treatment of HOCM
Feasibility of each approach
Institutional expertise
Patient characteristics
Anatomy (septum, papillary muscles, septal perforator, mitral valve)
Different mechanism
Size and location of septal reduction
Heterogeneous disease
SAM independent
SAM related
Anterior coaptation
Positive angle between LVOT and the leaflets
Chordal slack
Informed decision after detailed discussion about both therapies
OCM  hypertrophic obstructive cardiomyopathy; LVOT  left ventricular outflow tract; SAM 
ystolic anterior motion.gists with expertise in treating patients with HOCM. This
w
p
o
R
D
c
E
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
K
834 Agarwal et al. JACC Vol. 55, No. 8, 2010
Septal Alcohol Ablation Versus Septal Myectomy February 23, 2010:823–34ould go a long way in ensuring the safety and efficacy of this
rocedure, which can be very important in the armamentarium
f treatments for HOCM.
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